(OTCBB:ISCO)
For more information about International Stem Cell Corporation please visit our profile on irgnews.com: http://www.irgnews.com/coi/ISCO
International Stem Cell Corporation Reports Positive Pre-Clinical Trial Results From Human Corneal Epithelial Cells Trials Designed To Improve Laser Eye Surgery Outcomes, May 27, 2009
International Stem Cell Corporation Provides Comments On National Institutes of Health’s Proposed Stem Cell Research Guidelines, May 19, 2009
International Stem Cell Corporation (ISCO.OB) Announces the Release of DataTrends Equity Research Group Investor’s Corporate Profile® of the Company, May 14,2009
International Stem Cell Reports Excellent Preliminary Results for Skin Rejuvenation Skincare Product Resulted from Fundamental Pathenogenic Stem Cell Research, April 21,2009 International Stem Cell Corporation Receives Third $1M Tranche under a $5 Million Financing, March 17,2009
International Stem Cell Corporation enters into an Agreement with Cytograft Tissue Engineering to Develop a Therapeutic Medium for Cytograft’s Living Vascular Grafts Living laboratory grown blood vessels from the patient’s own cells, March 12,2009
Stem cell order may benefit biotechs, San Diego Union-Tribune, March 11,2009
Revival of Stem Cell Research Benefit Millions of Patients, THE NEWS, March 11,2009
International Stem Cell Corporation Applauds President Obama’s decision to allow funding of Parthenogenetic Stem Cell Research, March 10,2009
Industry set for stem cell profits (The Scientist.com, free registration required to view) March 9,2009
ISCO: CEO Comments on Obama's Lifting of Restrictions on Stem Cell Research, March 9,2009
International Stem Cell Corporation Hosts Webinar, Stem Cells 102: Beyond Embryonic Stem Cell Research, Thursday March 12, 2009, From 1:00pm-2:00pm EDT, March 6,2009
Parthenogenetic Stem Cells Poised to Break Through, Breakthrough Technology Alert by Patrick Cox, March 3,2009
DiscoveryBioMed, Inc. Engaged in Multiple Projects on Behalf of Lifeline Cell Technology, Inc. to Test the Function and Utility of Multiple Primary Human Cell Products, February 19,2009
International Stem Cell Corporation Issues Letter to Shareholders, February 5, 2009
International Stem Cell Corporation Featured In The Economist, February 3, 2009
StemCellPatents.Com Applauds ISCO, January 30, 2009
Embryonic Stem Cells... Can I serve You Now... The Economist, January 29, 2009
International Stem Cell Corporation Emerging as Major Player in Advancement of Stem Cell Research... Knobias Clip Report, January 29, 2009
International Stem Cell Corporation Begins Pre-Clinical Trials On Human Corneal Epithelial Cells, January 29, 2009
ISCO Emerging as Major Player in Advancement of Stem Cell Research, January 28, 2009
International Stem Cell Receives Second $1M Tranche Under $5 Million Financing, January 23, 2009
International Stem Cell Begins Pre-Clinical Testing of Its Parthenogenetic Stem Cells for Treatment of Retinal Disease...First Company To Grow Human Corneal Tissue From Stem Cells, January 13, 2009
International Stem Cell Corporation Discusses Recent Funding, January 5, 2009
International Stem Cell Corporation Releases Letter to Shareholders, October 23, 2008
International Stem Cell Corporation Retains The Investor Relations Group, October 22, 2008
International Stem Cell Corporation Announces a Manufacturing and Supply Agreement with Millipore Corporation, September 9, 2008
International Stem Cell Corporation Arranges $ 3 Million Equity Financing, August 21, 2008
Cohen Research Independent Analyst Report, July 29, 2008
Academia, For-Profits Team Up to Advance Stem Cell Research, San Diego Business Journal, July 28, 2008
International Stem Cell Corporation and Novocell, Inc. Collaborate to Test Human Parthenogenetic Stem Cells for production of Pancreatic Islet Cells that may be useful in the Treatment of Diabetes, July 17, 2008
International Stem Cell Corporation Announces Collaboration with Michigan State University to Study Parthenogenetic Stem Cells, July 8, 2008
International Stem Cell Corporation Signs Agreement with BioTime, Inc., and Embryome Sciences, Inc., to Provide Unique Human Stem Cell Lines for Research Use, June 25, 2008
International Stem Cell Corporation’s Human Parthenogenetic Stem Cells to be used in the Development of Treatments for Liver Disease May 14, 2008
International Stem Cell Corporation Obtains Exclusive Rights in the US and Canada to Distribute Approved Human Skin Model for Toxicity Testing April 29, 2008
International Stem Cell Corporation to Present at LD Micro Conference April 29, 2008
International Stem Cell Corporation Announces Collaboration with The University of Cambridge to Study Parthenogenetic Stem Cells, April 9, 2008.
BioTime to partner with International Stem Cell,East Bay Business Times, April 3, 2008.
International Stem Cell Corporation Announces Manufacturing and Supply Agreement with ATCC, March 31, 2008.
International Stem Cell Corporation’s Human Parthenogenetic Stem Cells to be used in Germany in the Development of Treatments for Neural Disease, February 28, 2008.
International Stem Cell Corporation to Present at Roth Capital Partners 20th Annual OC Growth Stock Conference, January 29, 2008.
International Stem Cell Corporation Chairman adds CEO Role, January 22, 2008.
International Stem Cell Corporation Chairman Kenneth Aldrich to be Interviewed on WALLST.NET, January 18, 2008.
International Stem Cell Corporation to Provide Corneal Epithelial Cells Differentiated from its Parthenogenetic Stem Cells For Use in Photorefractive Keratectomy (PRK) FDA Clinical Trials, January 14, 2008.
Human Embryonic Stem Cell Lines Created That Avoid Immune Rejection in Large Segments of the Population, December 18, 2007.
HLA Homozygous Stem Cell Lines Derived from Human Parthenogenetic Blastocysts, December 18, 2007. International Stem Cell Corporation CEO Issues Statement on De-Differentiation Research and Parthenogenesis, November 25, 2007.
International Stem Cell Names Noted Reproductive Endocrinologist to Scientific Advisory Board, September 17, 2007.
International Stem Cell Corporation Opens European Distribution Channel, Signs with CellSystems Biotechnologie Vertrieb, September 4, 2007. International Stem Cell Corporation Contracts to Manufacture Adipose-Derived Stem Cells for Cytori Therapeutics, August 20, 2007. International Stem Cell Corporation to Present at Roth Capital Partners New York Institutional Investor Conference September 5, 2007. International Stem Cell Corporation Quoted in Bloomberg article on its Parthenogenetic Stem Cells, August 2, 2007.
International Stem Cell Corporation Quoted in Scientific American on its Parthenogenetic Stem Cells, August 2, 2007.
Genetic Engineering News, July 12, 2007: Podcast: Deriving Bioidentical Human Stem Cells from Unfertilized Eggs - GEN’s Editor-in-Chief John Sterling interviews Jeffrey Janus, President, and Jeff Krstich, CEO, of International Stem Cell Corporation.
Associated Press, Thursday, June 28, 2007: Scientists: Stem cells created from Eggs
Bloomberg News: Thursday, June 28, 2007: International Stem Cell Shares Rise on New Cell Lines
Genetic Engineering News: June 27, 2007, Bioidential Human Stem Cells Derived from Unfertilized Eggs
Company-Issued News, June 27, 2007: Peer Review Paper Reporting Creation of Human Stem Cell Lines That Can Become Any Cell Type Using Unfertilized Eggs, Co-Authored by Scientists at International Stem Cell Corporation/Lifeline Cell Technology Appears in Cloning and Stem Cells Journal
Forbes.com, Thursday, June 28, 2007: Scientists: Stem Cells Created from Eggs
Mary Ann Liebert Publishers, June 26, 2007: Bioidentical Human Stem Cells Derived from Unfertilized Eggs
Cloning & Stem Cells Journal: June 26, 2007: Peer Review Scientific Paper: Patient-Specific Stem Cell Lines Derived from Human Parthenogenetic Blastocysts
Nature Magazine 5-24-07 International Stem Cell Corporation Subsidiary Lifeline Cell Technology Enters Into Agreement with University of California to Study Macular Degeneration and Retinitis Pigmentosa Mar. 19-07
Lifeline Cell Technology to Showcase Product Line at American Society for Cell Biology Conference Dec. 9-13, 2006 in San Diego
ISCO is the Parent Company of Lifeline Cell Technology
